Christopher H. van Dyck publications available on PubMed
ADRU Publications
The following are representative articles from Dr. van Dyck and the ADRU that highlight our research in the treatment, neuroimaging, and genetics of Alzheimer's disease and healthy aging:
- van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM, Seibyl JP, Innis RB, Arnsten AFT. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol Aging 2007, Mar 13.
- Zdanys KF , Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E e4 allele increases risk for psychotic symptoms in Alzheimer’s disease. Neuropsychopharmacology 2007;32(1):171-9.
- Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E e4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol Aging 2006;27(10):1416-24.
- van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in Alzheimer's disease patients maintained on donepezil. Am J Geriatr Psychiatry 2006; 14(5):428-437.
- van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J. Increased dopamine transporter availability associated with the 9-repeat allele of SLC6A3 gene. J Nucl Med 2005;46 745-751.
- Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal, LJ. Vitamin E and donepezil for the treatment of Mild Cognitive Impairment. N Engl J Med 2005;352(23):2379-2388.
- van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43.
- van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 2002;159(2):309-312.
- van Dyck CH, Newhouse P, Falk WE, Mattes JA: Extended-release physostigmine in Alzheimer's disease: a multicenter, double-blind, 12-week study with dose-enrichment. Arch Gen Psychiatry, 2000;57:157-164.